Table 1.
A list of clinical trials that have taken place or are currently ongoing in the US and Europe that combine radiation therapy with the listed DNA damage response (DDR) inhibitors. The phase of the trials, cancer types being investigated, current status as of submission, names of the drugs and the respective DDR targets, and trial identifier numbers have been listed
| Phase | Cancer | Status | Drug | Drug target | Trial identifier |
|---|---|---|---|---|---|
| I | Head and neck | Completed | Olaparib | PARP | NCT01758731 |
| I | Triple negative breast cancer | Recruiting | Olaparib | PARP | NCT03109080 |
| II | Inflammatory breast cancer | Recruiting | Olaparib | PARP | NCT03598257 |
| I | Inoperable breast cancer | Recruiting | Olaparib | PARP | NCT02227082 |
| I | Head and neck | Recruiting | Olaparib | PARP | NCT02229656 |
| I/II | Metastatic castration-resistant prostate cancer in bone | Recruiting | Olaparib | PARP | NCT03317392 |
| I | Soft-tissue sarcoma | Recruiting | Olaparib | PARP | NCT02787642 |
| I | Small cell lung cancer | Recruiting | Olaparib | PARP | NCT03532880 |
| I | Head and neck | Recruiting | Olaparib | PARP | NCT02308072 |
| I/II | Unresectable high-grade glioma | Recruiting | Olaparib | PARP | NCT03212742 |
| II | Glioblastoma | Ongoing | Olaparib | PARP | 2014-001216-19 |
| I/II | Diffuse pontine glioma | Completed | Veliparib | PARP | NCT01514201 |
| II | Non-small cell lung cancer with brain metastases | Completed | Veliparib | PARP | NCT01657799 |
| I | Peritoneal carcinomatosis, epithelial ovarian, fallopian, and primary peritoneal | Completed | Veliparib | PARP | NCT01264432 |
| I | Brain metastases | Completed | Veliparib | PARP | NCT00649207 |
| I | Rectal cancer | Completed | Veliparib | PARP | NCT01589419 |
| I | Recurrent breast cancer | Completed | Veliparib | PARP | NCT01477489 |
| II | Malignant glioma without H3 K27M or BRAFV600E mutations | Recruiting | Veliparib | PARP | NCT03581292 |
| I | Pancreatic | Active | Veliparib | PARP | NCT01908478 |
| I | Triple negative breast cancer | Recruiting | Rucaparib | PARP | NCT03542175 |
| I | Castrate-resistant prostate cancer | Recruiting | Niraparib | PARP | NCT03076203 |
| I | Non- and small cell lung cancer, and neuroendocrine | Recruiting | VX-970 (M6620) | ATR | NCT02589522 |
| I | Oesophageal and other | Not yet recruiting | VX-970 (M6620) | ATR | NCT03641547 |
| I | HPV-negative head and neck squamous cell carcinoma | Recruiting | VX-970 (M6620) | ATR | NCT02567422 |
| I | Brain cancer | Recruiting | AZD1390 | ATM | NCT03423628 |
| I | Advanced solid tumours | Recruiting | M3814 | DNA-PK | NCT03724890 |
| I | Advanced solid tumours | Recruiting | MSC2490484A | DNA-PK | NCT02516813 |
| I/II | Rectal cancer | Not yet recruiting | M3814 | DNA-PK | NCT03770689 |
| I | Head and neck | Recruiting | LY2606368 (Prexasertib) | CHK1/CHK2 | NCT02555644 |
| I | Head and neck | Recruiting | AZD1775 (Adavosertib) | WEE1 | NCT03028766 |
| I | Cervical, vaginal, and uterine | Recruiting | AZD1775 (Adavosertib) | WEE1 | NCT03345784 |
| I | Intermediate-/high-risk squamous head and neck | Recruiting | AZD1775 (Adavosertib) | WEE1 | NCT02585973 |
| I/II | Unresectable adenocarcinoma of the pancreas | Active | AZD1775 (Adavosertib) | WEE1 | NCT02037230 |
| I | Diffuse intrinsic pontine glioma | Recruiting | AZD1775 (Adavosertib) | WEE1 | NCT01922076 |
| I | Glioblastoma | Recruiting | AZD1775 (Adavosertib) | WEE1 | NCT01849146 |
| I | Soft-tissue sarcoma | Recruiting | AMG-232 | MDM2 | NCT03217266 |
| I/II | Non-small cell lung cancer | Completed | NFV | AKT | 2006-001031-22 |
PARP, poly (ADP-ribose) polymerase; ATR, ataxia telangiectasia and Rad3-related protein; ATM, ataxia-telangiectasia mutated; DNA-PK, DNA protein kinase; CHK, checkpoint kinase.
MDM2
AKT